CytomX Q1 Revenue Plummets 80% to $10.3M, Reports Positive Varseta-M Clinical Data
summarizeSummary
CytomX Therapeutics reported a significant financial downturn for Q1 2026, with revenue plummeting 80% year-over-year to $10.3 million and a net loss of $(0.10) per share, a sharp reversal from profit in the prior year. This substantial decline is attributed to the wind-down and termination of key collaboration agreements, aligning with the negative trends noted in the company's recent 10-K filing. However, the company also provided positive updates from its clinical pipeline, including promising Phase 1 data for Varseta-M, which showed a 32% objective response rate in late-line colorectal cancer. Furthermore, a recent $234 million equity raise has materially strengthened its balance sheet, extending its cash runway into at least the second half of 2028. Traders will weigh the severe financial contraction against the clinical progress and improved liquidity.
At the time of this announcement, CTMX was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $864.7M. The 52-week trading range was $0.91 to $8.21. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.